DB550 targets PLCγ1 and disrupts the CD95-PLCγ 1 interaction to prevent Th17-driven inflammation, without affecting the CD95-FADD interaction[1]. PLCγ1[1].
[1]. Poissonnier A, et al. Disrupting the CD95-PLCγ1 interaction prevents Th17-driven inflammation. Nat Chem Biol. 2018 Dec;14(12):1079-1089.
















